100 completed, 19 terminated, 8 unknown, 4 recruiting. 138 Phase 1, 30 Phase 2.
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-03-26 | 2026-10-20 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. ARV-393, Glofitamab - Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 1 | Recruiting | Arvinas Inc. | 329 | 2024-09-05 | 2026-09-04 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies anti-CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 14 | 2022-05-04 | 2025-06-06 |
| Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies anti-TRBC1 CAR-T cell therapy - Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Suspended | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 9 | 2021-03-31 | 2023-11-29 |
| CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study T cell injection targeting CD7 chimeric antigen receptor - T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type | Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 9 | 2020-11-24 | 2021-01-06 |
| Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Anti-CD30 CAR T cells - Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma | Phase 1 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 50 | 2019-07-03 | 2019-08-07 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-25 | 2026-10-29 |
| Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma AUTO4 - T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Terminated | Autolus Limited | 20 | 2018-08-30 | 2026-03-16 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 38 | 2017-11-14 | 2026-10-28 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine - Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2017-03-17 | 2023-01-18 |
| CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma anti-CD7 CAR-pNK cells - Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-03-01 | 2016-12-06 |
| Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 1 / Phase 2 | Completed | University of Nebraska | 54 | 2015-09-28 | 2023-12-13 |
| Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Dasatinib - Non-Hodgkin's Lymphoma, Multiple | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 8 | 2015-02-12 | 2020-03-16 |
Showing 20 of 138. Sign in to see all of them.
Lymphoma, Large-Cell, Anaplastic (128) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (107) · Lymphoma, Large B-Cell, Diffuse (103) · Lymphoma, Follicular (98) · Lymphoma, Mantle-Cell (97) · Burkitt Lymphoma (96) · Leukemia, Lymphocytic, Chronic, B-Cell (96) · Lymphoma, B-Cell, Marginal Zone (95) · Hodgkin Disease (94) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (94) · Lymphoma, T-Cell, Cutaneous (92) · Mycosis Fungoides (92) · Lymphoma, Non-Hodgkin (91) · Sezary Syndrome (87)
Hemic and Lymphatic Diseases (138) · Immune System Diseases (138) · Immunoproliferative Disorders (138) · Lymphadenopathy (138) · Lymphatic Diseases (138) · Neoplasms by Histologic Type (137) · Neoplasms (134) · Lymphoproliferative Disorders (130) · Hematologic Diseases (118) · Leukemia, Lymphoid (115) · Lymphoma, T-Cell (113) · Lymphoma, B-Cell (108) · Disease Attributes (104) · Pathologic Processes (104) · Pathological Conditions, Signs and Symptoms (104)
Cyclophosphamide (12) · Bortezomib (10) · Doxorubicin (8) · Carboplatin (7) · Peripheral Blood Stem Cell Transplantation (7) · Vincristine (7) · Etoposide (6) · Everolimus (6) · Prednisone (6) · Vorinostat (6) · fludarabine phosphate (6) · Filgrastim (5) · Lenalidomide (5) · Azacitidine (4) · Cyclosporine (4)
National Cancer Institute (NCI) (36) · National Institutes of Health Clinical Center (CC) (6) · City of Hope Medical Center (5) · M.D. Anderson Cancer Center (5) · Memorial Sloan Kettering Cancer Center (5) · Mayo Clinic (4) · Fred Hutchinson Cancer Center (3) · Northwestern University (3) · University of Medicine and Dentistry of New Jersey (3) · Barbara Ann Karmanos Cancer Institute (2) · Cancer Research UK (2) · Jonsson Comprehensive Cancer Center (2) · Massachusetts General Hospital (2) · NYU Langone Health (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2)
United States (120) · China (7) · Canada (6) · Italy (4) · United Kingdom (3) · France (2) · Germany (2) · Japan (2) · South Korea (2) · Spain (2) · Australia (1) · Denmark (1) · Singapore (1) · Switzerland (1)
Shivaani Kummar, MD (4) · Roger Strair, MD, PhD (3) · Abhinav Deol, M.D. (2) · David R. Spriggs, MD (2) · Leonard B. Saltz, MD (2) · Mace L. Rothenberg, MD, FACP (2) · Mario Sznol, MD (2) · Michael A. Carducci, MD (2) · Ramesh Ramanathan (2) · Samuel Y Ng, M.D. (2) · Aaron R Mangold, M.D. (1) · Adam Petrich, MD (1) · Ajay Gopal (1) · Alan P. Venook, MD (1) · Alex A. Adjei, MD, PhD (1)
PMID 32499241, PMID 11410496, PMID 14630685, PMID 16135477, PMID 17119113, PMID 18327587, PMID 18463792, PMID 19451403, PMID 19789320, PMID 21247755, PMID 21498721, PMID 22259028, PMID 23256542, PMID 23393050, PMID 24057042, PMID 24241210, PMID 24352795, PMID 24474568, PMID 24530972, PMID 25213183, PMID 26659919, PMID 26943915, PMID 28054442, PMID 28103725, PMID 28270022, PMID 28314788, PMID 29292843, PMID 29622656, PMID 30773077, PMID 31617432, PMID 33492438, PMID 35175355, PMID 36898933, PMID 37939262, PMID 39528665, PMID 39821757, PMID 9628848
P30CA033572 (4), U01CA062491 (4), U01CA076576 (4), U01CA099168 (4), P30CA014520 (3), P30CA015083 (3), P30CA015704 (3), P30CA016058 (3), P30CA016672 (3), P30CA072720 (3), U01CA062487 (3), U01CA062505 (3), U10CA032102 (3), P30CA008748 (2), P30CA016087 (2)